ATM and neoplasm: Together the in vitro and in vivo data demonstrate pre-clinical synergy between olaparib and AZD6738 in ATM-deficient tumours and provide a mechanistic rationale for clinically targeting tumours with ATM-inactivating mutations across multiple tissue types.